Improving Outcomes in Hodgkin Lymphoma

This in-depth discussion, presented by Louis Diehl, MD, Professor of Medicine at Duke University Medical School, will feature strategies for incorporating predictive and prognostic markers, recent efficacy and safety data, and adverse event management strategies into treatment selection for patients with Hodgkin lymphoma (HL). Start the activity now.

STATEMENT OF NEED

Hodgkin lymphoma (HL) is a rare malignancy of the lymph nodes and lymphatic system, with about 8,830 new cases diagnosed each year in the United States (Siegel et al, 2021). While the advent of novel therapies is leading to significantly improved outcomes, HL treatment continues to be associated with an increased risk for secondary cancers and cardiovascular disease(NCCN, 2021; Kreissl et al, 2020). In order to minimize long-term treatment effects and maximize health-related quality of life for patients with HL, clinicians need to stay abreast of newly established recommendations and evolving data. In this activity, Louis F. Diehl, MD, will update clinicians on developing evidence-based HL management plans tailored to individual patients and their long-term care needs.

TARGET AUDIENCE

Hematologist/oncologists, hematology/oncology fellows, nurse practitioners, physician assistants, pharmacists, oncology nurses, and other health care professionals involved in the treatment of patients with hematologic malignancies.

LEARNING OBJECTIVES

Discuss predictive and prognostic markers that can individualize treatment selection for patients with HL
Assess emerging efficacy and safety data on novel therapeutic strategies for HL
Evaluate strategies to optimize the safety and tolerability of novel therapies for HL